- •Atrial fibrillation (AF) causes cardiogenic embolism which is the critical complication.
- •Oral anticoagulation (OAC) plays a central role in reducing stroke risk in AF patients.
- •There is a subset of patients who cannot tolerate OAC due to high-bleeding risk.
- •One of the promising non-pharmacological therapies is left atrial appendage closure (LAAC).
- •LAAC may be an alternative therapy to avoid stroke for AF patients with high bleeding risk by OAC.
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice and its prevalence increases with age. AF causes palpitations, heart failure, and cardiogenic embolism. Of them, the most critical and fatal complication is a cardio-embolic event. Oral anticoagulation plays a central role in reducing stroke risk in AF patients. Recently, when oral anticoagulation is considered in patients with non-valvular AF who are eligible for direct oral coagulations, they are preferred to vitamin K antagonist based on accumulating evidence. Although many patients can tolerate oral anticoagulation, there is a subset of patients who cannot tolerate long-term oral anticoagulation. Such a subset has a higher bleeding risk as indicated by the HAS-BLED score under oral anticoagulation. This subset of patients requires effective and safe non-pharmacological alternative therapies for stroke prevention. One of the promising non-pharmacological therapies is left atrial appendage closure. Three randomized controlled trials demonstrated non-inferiority of percutaneous left atrial appendage closure using WATCHMAN family to oral anticoagulation (Boston Scientific, Marlborough, MA, USA). WATCHMAN FLX, which was innovated following WATCHMAN 2.5, was associated with fewer safety events and a higher success rate of effective appendage closure. Nevertheless, several unsolved issues remain, including device-related thrombosis, post-treatment antithrombotic therapy, and peri-device leakage. Left atrial appendage closure for patients with non-valvular AF may be an alternative therapy to avoid cardiac embolism for high bleeding risk patients with contraindications to long-term oral anticoagulation therapy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cardiology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination.Int J Cardiol. 2009; 137: 102-107
- American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2019 update: a report from the American Heart Association.Circulation. 2019; 139: e56-e58
- 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).Eur Heart J. 2021; 42: 373-498
- JCS/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias.Circ J. 2022; 86: 1790-1924
- A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.Chest. 2010; 138: 1093-1100
- Left atrial appendage studied by computed tomography to help planning for appendage closure device placement.J Cardiovasc Electrophysiol. 2010; 21: 973-982
- Left atrial appendage size in patients with atrial fibrillation in Japan and the United States.Heart Vessels. 2021; 36: 277-284
- The left atrial appendage: anatomy, function, and noninvasive evaluation.J Am Coll Cardiol Img. 2014; 7: 1251-1265
- Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study.J Am Coll Cardiol. 2012; 60: 531-538
- Morphology of the left atrial appendage: prevalence and gender difference in a Kenyan population.J Morphol Sci. 2018; 35: 48-53
- Complex left atrial appendage morphology and left atrial appendage thrombus formation in patients with atrial fibrillation.Circ Cardiovasc Imaging. 2014; 7: 337-343
- Left atrial appendage: structure, function, and role in thromboembolism.Heart. 1999; 82: 547-555
- Five-year experience with the maze procedure for atrial fibrillation.Ann Thorac Surg. 1993; 56: 814-823
- Atrial and brain natriuretic peptide secretion after percutaneous closure of the left atrial appendage with the watchman device.J Invasive Cardiol. 2015; 27: 448-452
- Mechanical closure of the left atrial appendage: is it time to be more aggressive?.J Thorac Cardiovasc Surg. 2013; 146: 1018-1027
- Utility of transesophageal echocardiography in identification of thrombogenic milieu in patients with atrial fibrillation (an ACUTE ancillary study).Am J Cardiol. 2005; 96: 935-941
- Left atria1 appendage thrombus is not uncommon in patients with acute atria1 fibrillation and a recent embolic event: a transesophageal echocardiographic study.J Am Coll Cardiol. 1995; 25: 452-459
- The Society of Thoracic Surgeons 2017 clinical practice guidelines for the surgical treatment of atrial fibrillation.Ann Thorac Surg. 2017; 103: 329-341
- Meta-analysis evaluating outcomes of surgical left atrial appendage occlusion during cardiac surgery.Am J Cardiol. 2019; 124: 1218-1225
- Surgical management of the left atrial appendage: a must or a myth?.Eur J Cardiothorac Surg. 2018; 53: i33-i38
- Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke.Am Heart J. 2005; 150: 288-293
- Left atrial appendage occlusion during cardiac surgery to prevent stroke.N Engl J Med. 2021; 384: 2081-2091
- Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.JAMA. 2014; 312: 1988-1998
- Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.J Am Coll Cardiol. 2014; 64: 1-12
- Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation.J Am Coll Cardiol. 2020; 75: 3122-3135
- Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.JAMA. 2001; 285: 2864-2870
- 5-Year outcomes after left atrial appendage closure from the PREVAIL and PROTECT AF trials.J Am Coll Cardiol. 2017; 70: 2964-2975
- Percutaneous WATCHMAN left atrial appendage closure for Japanese patients with nonvalvular atrial fibrillation at increased risk of thromboembolism. First results from the SALUTE trial.Circ J. 2018; 82: 2946-2953
- 4-Year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation.J Am Coll Cardiol. 2022; 79: 1-14
- Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial.Circulation. 2021; 143: 1754-1762
- Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study.Ann Intern Med. 1995; 123: 817-822
- Multidetector computed tomography may be an adequate screening test to reduce periprocedural stroke in atrial fibrillation ablation: a multicenter propensity-matched analysis.Heart Rhythm. 2014; 11: 763-770
- Comparing measurements of CT angiography, TEE, and fluoroscopy of the left atrial appendage for percutaneous closure.J Cardiovasc Electrophysiol. 2016; 7: 414-422
- Usefulness of 'figure-of-eight' suture to achieve haemostasis after removal of 15-French calibre femoral venous sheath in patients undergoing cryoablation.Europace. 2016; 18: 1545-1550
- Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix feasibility study with watchman left atrial appendage closure technology).J Am Coll Cardiol. 2013; 61: 2551-2556
- Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicenter, monitored international WATCHMAN LAA closure registry.EuroIntervention. 2017; 13: 877-884
- Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN.JACC Cardiovasc Interv. 2019; 12: 1055-1063
- Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion.JACC Cardiovasc Interv. 2021; 14: 2353-2364
- Device-related thrombus following left atrial appendage occlusion.EuroIntervention. 2022; 18: 224-232
- Predictors of device-related thrombus following percutaneous left atrial appendage occlusion.J Am Coll Cardiol. 2021; 78: 297-313
- Device thrombosis after percutaneous left atrial appendage occlusion is related to patient and procedural characteristics but not to duration of postimplantation dual antiplatelet therapy.Circ Cardiovasc Interv. 2018; 11e005997
- Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) Clinical Trial and the Continued Access Registry.Circulation. 2011; 123: 417-424
- Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation.J Am Coll Cardiol. 2018; 71: 1528-1536
- Device-associated thrombus formation after left atrial appendage occlusion: a systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet.Catheter Cardiovasc Interv. 2017; 90: E111-E121
- Left atrial appendage occlusion with the AMPLATZER amulet device: an expert consensus step-by-step approach.EuroIntervention. 2016; 11: 1512-1521
- Intracardiac echocardiography in structural heart disease interventions.Am Coll Cardiol Interv. 2018; 11: 2133-2147
Published online: November 24, 2022
Accepted: October 25, 2022
Received: October 25, 2022
Publication stageIn Press Corrected Proof
© 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. All rights reserved.